Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pierre Goldbach is active.

Publication


Featured researches published by Pierre Goldbach.


Journal of Pharmaceutical Sciences | 2012

Analytical protein A chromatography as a quantitative tool for the screening of methionine oxidation in monoclonal antibodies

Caroline Loew; Constanze Knoblich; Jürgen Fichtl; Nadja Alt; Katharina Diepold; Patrick Bulau; Pierre Goldbach; Michael Adler; Hanns-Christian Mahler; Ulla Grauschopf

The presence of oxidized methionine residues in therapeutic monoclonal antibodies can potentially impact drug efficacy, safety, as well as antibody half-life in vivo. Therefore, methionine oxidation of antibodies is a strong focus during pharmaceutical development and a well-known degradation pathway. The monitoring of methionine oxidation is currently routinely performed by peptide mapping/liquid chromatography-mass spectrometry techniques, which are laborious and time consuming. We have established analytical protein A chromatography as a method of choice for fast and quantitative screening of total Fc methionine oxidation during formulation and process development. The principle of this method relies on the lower binding affinity of protein A for immunoglobulin G-Fc domains containing oxidized methionines, compared with nonoxidized Fc domains. Our data reveal that highly conserved Fc methionines situated close to the binding site to protein A can serve as marker for the oxidation of other surface-exposed methionine residues. In case of poor separation of oxidized species by protein A chromatography, analytical protein G chromatography is proposed as alternative. We demonstrate that analytical protein A chromatography, and alternatively protein G chromatography, is a valuable tool for the screening of methionine oxidation in therapeutic antibodies during formulation and process development.


Journal of Pharmaceutical Sciences | 2015

Freeze Drying of l-Arginine/Sucrose-Based Protein Formulations, Part I: Influence of Formulation and Arginine Counter Ion on the Critical Formulation Temperature, Product Performance and Protein Stability

Peter Stärtzel; Henning Gieseler; Margit Gieseler; Ahmad M. Abdul‐Fattah; Michael Adler; Hanns-Christian Mahler; Pierre Goldbach

The objective of this study was to investigate product performance of freeze dried l-arginine/sucrose-based formulations under variation of excipient weight ratios, l-arginine counter ions and formulation pH as a matrix to stabilize a therapeutic monoclonal antibody (MAb) during freeze drying and shelf life. Protein and placebo formulations were lyophilized at aggressive primary drying conditions and key attributes of the freeze dried solids were correlated to their thermal properties and critical formulation temperature. Stability (physical) during processing and long-term storage of the MAb in different formulations was assessed by SE-HPLC. Thermal properties of the mixtures were greatly affected by the type of l-arginine counter ion. High glass transition temperatures were achieved by adding multivalent acids, whereas the temperature values significantly decreased in the presence of chloride ions. All mixtures were stable during freeze drying, but storage stability varied for the different preparations and counter ions. For l-arginine-based formulations, the protein was most stable in the presence of chloride ion, showing no obvious correlation to estimated global mobility of the glass. Besides drying behavior and thermal properties of the freeze dried solids, the counter ion of l-arginine must be considered relevant for protein shelf life stability.


Journal of Pharmaceutical Sciences | 2015

Freeze-Drying of l-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an l-Arginine Chloride-Based Protein Formulation System

Peter Stärtzel; Henning Gieseler; Margit Gieseler; Ahmad M. Abdul-Fattah; Michael Adler; Hanns-Christian Mahler; Pierre Goldbach

We recently reported that the presence of chloride counter ions in freeze-dried l-arginine/sucrose formulations provided the greatest protein stability, but led to low collapse temperatures and glass transition temperatures of the freeze concentrates. The objectives of this study were to identify l-arginine chloride-based formulations and optimize freeze-drying process conditions to deliver a freeze-dried product with good physical quality attributes (including cake appearance, residual moisture, and reconstitution time). Additional properties were tested such as thermal properties, cake microstructure, and protein physical stability. Excipient concentrations were varied with and without a model protein (bovine serum albumin, BSA). Formulations were frozen with and without annealing or with and without controlled nucleation. Primary drying was conducted at high and low shelf temperature. Cakes with least defects and optimum physical attributes were achieved when protein to excipient ratios were high. Controlled nucleation led to elegant cakes for most systems at a low shelf temperature. Replacing BSA by a monoclonal antibody showed that protein (physical) stability was slightly improved under stress storage temperature (i.e., 40°C) in the presence of a low concentration of l-arginine in a sucrose-based formulation. At higher l-arginine concentrations, cake defects increased. Using optimized formulation design, addition of l-arginine chloride to a sucrose-based formulation provided elegant cakes and benefits for protein stability.


American Journal of Health-system Pharmacy | 2015

In-use physicochemical and microbiological stability of biological parenteral products

Margaret Speed Ricci; Michelle Frazier; Jamie M.R. Moore; Mary Cromwell; William J. Galush; Ankit R. Patel; Michael Adler; Ulrike Altenburger; Ulla Grauschopf; Pierre Goldbach; Jonas L. Fast; Irene Krämer; Hanns-Christian Mahler

Pharmaceutical scientists in the biotechnology industry have traditionally focused on achieving acceptable shelf lives of drug products in their original, unopened product unit configuration (e.g., two years stored at 2–8 °C). However, it is now clear that stability considerations extend beyond


Journal of Pharmaceutical Sciences | 2018

Imaging techniques to characterize cake appearance of freeze-dried products

Christina Roswitha Haeuser; Pierre Goldbach; Joerg Huwyler; Wolfgang Friess; Andrea Allmendinger

Pharmaceutically elegant lyophilisates are highly desirable implying a stable and robust freeze-drying process. To ensure homogenous and intact cake appearance after process scale-up and transfer, characterization of lyophilisates during formulation and cycle development is required. The present study investigates different imaging techniques to characterize lyophilisates on different levels. Cake appearance of freeze-dried bovine serum albumin formulations with different dextran/sucrose ratios was studied by visual inspection, three-dimensional laser scanning, polydimethylsiloxane embedding, scanning electron microscopy, and microcomputed tomography (μ-CT). The set of techniques allowed a holistic evaluation of external cake appearance and internal structure providing complementary information at macroscopic and microscopic scale. In comparison to state of the art technologies like visual inspection or scanning electron microscopy, three-dimensional laser scanning and μ-CT provided quantitative information allowing comparison of visual cake appearance. In particular μ-CT enables a global, qualitative, and quantitative characterization of external and internal cake structure with a single measurement detecting heterogeneities of lyophilisates. We even demonstrated the use of noninvasive μ-CT for qualitative imaging of internal cake structure through the glass vial. Providing meaningful characterization of the entire lyophilisate, μ-CT can serve as a powerful tool during development of freeze-drying cycles, process scale-up, and transfer.


Archive | 2007

Abeta antibody parenteral formulation

Pierre Goldbach; Hanns-Christian Mahler; Robert Mueller; Christine Wurth


Archive | 2009

Method and formulation for reducing aggregation of a macromolecule under physiological conditions

Brian Lobo; Sabrina Lo; Aditya Wakankar; Yuchang John Wang; Rita L. Wong; Pierre Goldbach; Hanns-Christian Mahler


Journal of Pharmaceutical Sciences | 2016

Mannitol/l-Arginine-Based Formulation Systems for Freeze Drying of Protein Pharmaceuticals: Effect of the l-Arginine Counter Ion and Formulation Composition on the Formulation Properties and the Physical State of Mannitol.

Peter Stärtzel; Henning Gieseler; Margit Gieseler; Ahmad M. Abdul-Fattah; Michael Adler; Hanns-Christian Mahler; Pierre Goldbach


International journal of pharmaceutical compounding | 2015

Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials

Claudia Mueller; Elde Dietel; Severin R Heynen; Heiko Nalenz; Pierre Goldbach; Hanns-Christian Mahler; Johannes Schmidt; Ulla Grauschopf; Karin Schoenhammer


Archive | 2008

Polymorphic Forms of Oseltamivir Phosphate

Pierre Goldbach; Olaf Grassmann; Ines Sauer

Collaboration


Dive into the Pierre Goldbach's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Henning Gieseler

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Peter Stärtzel

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge